130209-82-4

Basic information

• Product Name: Latanoprost
• Synonyms: XALATAN;ISOPROPYL (5Z, 9A,11A,15R)-9,11,15-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5Z-EN-1-OATE;LATANOPROST;17-PHENYL-13,14-DIHYDRO TRINOR PROSTAGLANDIN F2ALPHA ISOPROPYL ESTER;9ALPHA,11ALPHA,15R-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5Z-EN-1-OIC ACID, ISOPROPYL ESTER;9ALPHA, 11ALPHA, 15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROS-5Z-EN-1-OIC ACID, ISOPROPYL ESTER;(1r-(1-alpha(z),2-beta(r*),3-alpha,5-alpha))--methylethyleste;7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoicaci1
• CAS NO: 130209-82-4
• Molecular Formula: C₂₆H₄₀O₅
• Molecular Weight: 432.59
• EINECS: 1806241-263-5
• Product Categories: Active Pharmaceutical Ingredients;Prostaglandins;Prostaglandin;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Inhibitors;Key Products
• Mol File: 130209-82-4.mol
• Article Data: 48

Chemical Properties

• Boiling Point: 583.8 °C at 760 mmHg
• Flash Point: 188.3 °C
• Appearance: pale yellow/oil
• Density: 1.093 g/cm³
• Refractive Index: 1.537
• Storage Temp.: −20°C
• Solubility: DMSO: freely soluble
• PKA: 14.84±0.70(Predicted)
• Water Solubility: DMSO: freely soluble
• Merck: 14,5376
• CAS DataBase Reference: Latanoprost(CAS DataBase Reference)
• NIST Chemistry Reference: Latanoprost(130209-82-4)
• EPA Substance Registry System: Latanoprost(130209-82-4)

Safety Data

• WGK Germany: 3
• RTECS: MJ9669550
• Hazardous Substances Data: 130209-82-4(Hazardous Substances Data)

Usage

a prostaglandin F2a analogue

Latanoprost is a prostaglandin F2a analogue.It is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. It is used to treat certain kinds of glaucoma(open-angle glaucoma ocular hypertension). It is also used to treat a condition called hypertension of the eye. Latanoprost is used to increase the natural outflow of fluid (aqueous humor) from inside the eye into the bloodstream. It appears to work by increasing the outflow of fluid from the eye. This lowers the pressure in the eye. Latanoprost may make your eyesight blurred for a short length of time. if this happens do not drive or operate machine or use any tools until your eye sight becomes clear again.

Latanoprost ophthalmic solution

Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It is also known by the brand name of Xalatan manufactured by Pfizer.For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution contain a preservative called benzalkonium chloride which can be absorbed onto the surface of contact lenses and may discolour soft contact lenses.

Side effects

Between 6% and 10% (between 1 in 20 and 1 in 6) of persons receiving latanoprost for 6 months report at least one side effect localized to the eyes. These side effects included Temporary blurred vision after application, eyelid redness, permanently darken eyelashes,Swelling or erosions of the cornea,a sensation of a foreign body, discoloration of the iris, itching, a temporary burning sensation during use, and stinging. Discoloration of the iris begins happens slowly. It is caused by an increase in the amount of brown pigment in the iris and may be permanent. Other side effects which have been reported less frequently include dryness of the eyes, increased tearing, herpes simplex keratitis, eye pain and other eye-related discomfort.

Product description

Latanoprost is a novel anti-glaucoma drugs which is suitable for the treatment of primary open-angle glaucoma or the tropical treatment of patients of ocular hypertension which is difficult to be treated and tolerated. It also has excellent efficacy in treating pigment dispersion glaucoma, angle recession, chronic angle-closure glaucoma, uveitis and quiescent exfoliation syndrome but is invalid for treating of uveitis in its active stage. Latanoprost is a kind of prostaglandin F2α derivative and is a kind of selective F2α receptor agonist. It is a non-active substance but can quickly penetrate into the cornea. It can be hydrolyzed into active free acid in the cornea and the plasma. It can increase the outflow amount of aqueous chambers water through the corner keratin layer. It only needs a small dose has a significant effect in boosting the outflow amount of the aqueous chambers water. The drug liquid can penetrate into the eyeball eyelashes suprachoroidal with excellent intraocular pressure lowering effect. Glaucoma will also clear the clogged trabecular mesh of patients.

Molecular Structure

Latanoprost contains a pentene ring which has α-and ω-carbon chain with the ester of the α-carbon chain termini in the structure can facilitate its penetration through the cornea. At the corneal stroma, latanoprost can be decomposed into free acid which can bind to the FP receptor as the active part. It has hydroxyl group in C15, and has a short ω-chain and a benzene ring which are important for the efficacy of the drug.

Adverse reactions and side effects

Topical administration can result in mild to moderate conjunctival or scleral hyperemia. Occasionally slight redness on eyes can be observed. During the treatment of the first 2-3 days, the eyes will have a slight foreign body sensation; a small number of patients may get rash.

Chemical Properties

It is a kind of colorless oil. [α] D20 + 31.57 ° (C = 0.91, acetonitrile).

Uses

Different sources of media describe the Uses of 130209-82-4 differently. You can refer to the following data:
1. It can be used for the treatment of glaucoma.
2. Prostanoid receptor ligand
3. antifungal polyene macrolide that is active in the cell membrane soluble 5% Acetic acid
4. Latanoprost is the isopropyl ester of 17-phenyl-13,14-dihydro prostaglandin F2α (17-phenyl-13,14-dihydro PGF2α). It is a prodrug form of the free acid, which is a potent agonist of the FP receptor in the eye. Latanoprost reduces intraocular pressure in glaucoma patients with few side effects. The EC50 value of latanoprost (tested as the free acid) for FP receptors is 3.6 nM.
5. Prostaglandin analog, used to treat glaucoma and other degenerative diseases of the eye.

Production method

First dissolve the compound (Ⅰ) in toluene, cool to 18 °C, further add dicyclohexyl carbodiimide (DCC) and phosphoric acid, followed by addition of (4-phenyl-3-oxobutyl) triphenylphosphonium iodide with condensation being converted to compound (II) which is further converted to the product through the six-step reaction.

Description

Xalatan was launched in Sweden, Switzerland and the US for the treatment of glaucoma. It can be synthesized, from the Corey lactone, using standard prostaglandin chemistry. Latanoprost is a PGF2α, analog that is more lipophilic thus is better able to penetrate the cornea. The (15R)-diastereomer has only 10% of the activity compared to the (15S)-diastereomer. It is a selective FP receptor agonist with little or no effect on the other prostanoid receptors. The antiglaucoma effects are the result of reduced intraocular pressure arising by increasing uveoscleral outflow with little or no effect on trabeculo-canalicular aqueous outflow and no effect on retinal vasculation or permeability of the blood-aqueous barrier. The topical application is sufficient for a single daily dosage and is well tolerated with no detectible conjunctival hyperaemia.

Originator

Pharmacia & pjohn (UK)

Definition

ChEBI: A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.

Manufacturing Process

Manufacturing process for Latanoprost includes these steps as follows: Synthesis of [3aR-[3aα,4α(E),5β,6aα]]-5-(benzoyloxy) hexahydro-4-(3-oxo-5-phenyl-1-pentenyl)-2H-cyclopenta[b]furan-2-one, synthesis of [3aR-[3aα,4a(1E,3S),5β,6aα]]-5-(benzoyloxy)hexahydro- 4-(3 -hydroxy-5-phenyl-1-pentenyl)-2H-cyclopenta[b]furan-2-one, synthesis of [3aR-[3aα,4a(1E,3S),5β,6aα]]- 5-(benzoyloxy)hexahydro-4-(3-hydroxy-5-phenyl-1-pentyl)-2Hcyclopenta[b]furan-2-one, synthesis of 2-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5- phenylpentyl]cyclopentyl]acetic acid, synthesis of [3aR-[3aα,4α(R),5β,6aα]]-hexahydro-5-hydroxy-4-(3-hydroxy-5- phenylpentyl)-2H-cyclopenta[b]furan-2-one, synthesis of [3aR-[3aα,4α(R),5β,6aα]]- hexahydro-5-hydroxy-4-(3-hydroxy-5-phenylpentyl)-2H-cyclopenta[b]furan-2-one;synthesis of (3aR,4R,5R,6aS)-5- (1-ethoxyethoxy)-4-[(3R)-3-(1-ethoxyethoxy)-5-phenylpentyl]hexahydro-2Hcyclopenta[b]furan-2-ol;synthesis of 7-[(1R,2R,3R,5S)-3-(1-ethoxyethoxy)-5- hydroxy-2-[(3R)-3-(1-ethoxyethoxy)-5- phenylpentyl]cyclopentyl-5-heptenoic acid; synthesis of (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5- phenylpentyl]cyclopentyl]-5-heptenoic acid (Latanoprost Acid); At last, Latanoprost acid is dissolved in DMF (10 mL) and added to a slurry of cesium carbonate (1.6 g) in DMF (10 mL). 2-Iodopropane (0.49 mL) is added and the slurry is heated to 45°C for about 6 hours. When the reaction is complete, MTBE (40 mL) and water (50 mL) are added and the mixture is stirred for 15 min. The phases are separated and the aqueous phase is washed with MTBE (20 mL). The organic phases are combined and concentrated. The concentrate is chromatographed (silica gel) eluting with MTBE. The appropriate fractions are pooled and concentrated to give (5Z)-(9CI)-7-[(1R,2R,3R,5S)-3,5- Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl ]cyclopentyl]-5-heptenoic acid 1- methylethyl ester (Latanoprost).

Brand name

Xalatan (Pharmacia & Upjohn).

Therapeutic Function

Antiglaucoma

General Description

Latanoprost (Xalatan) is available as a 0.005% sterileophthalmic solution in a 2.5-mL dispenser bottle.Latanoprost is also marketed as a combination ophthalmicproduct with the β-adrenergic blocking agent, timolol,which apparently enhances IOP-lowering by decreasing theproduction of aqueous humor. Cautions and side effects aresimilar to those for other ophthalmic prostanoids.

Biochem/physiol Actions

Latanoprost is a potent, selective prostaglandin F2α?analog receptor agonist. It is hydrolyzed by esterases into its biologically active form latanoprost acid in the cornea. Latanoprostplays a role in reducing the intraocular pressure (IOP) due to which it has therapeutic effects in treating glaucoma.

Safety Profile

A poison by ingestion and intravenous route. Human systemic effects. When heated to decomposition it emits acrid smoke and irritating vapors.

InChI:InChI=1/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/t21-,22+,23+,24-,25+/m0/s1

Synthetic route

2-iodo-propane (75-30-9) + latanoprost acid (41639-83-2) → isopropyl (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + latanoprost (130209-82-4)

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetone at 20℃; for 14h;	A n/a B 99.83%

latanoprost acid (41639-83-2) + isopropyl alcohol (67-63-0) → latanoprost (130209-82-4)

Conditions	Yield
With Lipase Novozym 435 at 30℃; for 18h; Enzymatic reaction;	92%
Novozym 435 at 30℃; for 18h;	92%
With 2-chloro-1,3-dimethyl imidazolium chloride; potassium tert-butylate; triethylamine at 0 - 70℃; for 2h;

isopropyl 11,15-bistetrahydropyranyloxy-13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2α → latanoprost (130209-82-4)

Conditions	Yield
With pyridinium p-toluenesulfonate In methanol at 52℃; for 4h; Product distribution / selectivity;	90%
pyridinium p-toluenesulfonate In methanol at 52℃; for 4h;	90%
With pyridinium p-toluenesulfonate In dichloromethane at 40℃; Inert atmosphere;	86.1%
With toluene-4-sulfonic acid In isopropyl alcohol at 40℃; for 5h;
With ethanol; pyridinium p-toluenesulfonate at 20 - 50℃; for 3h;

2-iodo-propane (75-30-9) + latanoprost acid (41639-83-2) → latanoprost (130209-82-4)

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;	84%
With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 14h;	72%
With potassium carbonate In N,N-dimethyl-formamide at 50℃;	68%

C41H64O8 (856453-33-3) → latanoprost (130209-82-4)

Conditions	Yield
With pyridinium p-toluenesulfonate In methanol at 45℃; for 6h; Product distribution / selectivity;	83.7%
pyridinium p-toluenesulfonate In methanol at 45℃; for 6h;	83.7%

C39H46O7 → latanoprost (130209-82-4)

Conditions	Yield
Stage #1: C39H46O7 With hydrogen In ethyl acetate at 20℃; for 4h; Inert atmosphere; Stage #2: With 2,3-dicyano-5,6-dichloro-p-benzoquinone In dichloromethane; water at 0℃; for 0.5h; Inert atmosphere; Stage #3: With sodium tetrahydroborate In methanol; dichloromethane; water at 0℃; for 2.5h; Inert atmosphere;	83%

C26H38O5 (141074-06-8) → latanoprost (130209-82-4)

Conditions	Yield
Stage #1: C26H38O5 With 2,6-di-tert-butyl-4-methyl-phenol; diisobutylaluminium hydride In toluene at -70 - -20℃; Stage #2: With hydrogenchloride In water; toluene	75%

2-iodo-propane (75-30-9) + latanoprost acid (41639-83-2) → isopropyl (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + latanoprost (130209-82-4)

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetone at 20℃; for 5.5 - 14.2167h; Product distribution / selectivity;	A n/a B n/a C 63.2%

2-iodo-propane (75-30-9) + C23H32O4 → latanoprost (130209-82-4)

Conditions	Yield
Stage #1: C23H32O4 With sodium hydride In isopropyl alcohol; mineral oil at 20 - 35℃; for 18h; Stage #2: 2-iodo-propane With 1,8-diazabicyclo[5.4.0]undec-7-ene In tetrahydrofuran at 20℃; for 18h;	49%

(3aR,4R,5R,6aS)-hexahydro-5-triethylsilyoxy-4-[5-phenyl-(3R)-3-triethylsilyloxy-pentanyl]-2H-cyclopenta[β]furan-2-one (477884-73-4) → isopropyl (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + latanoprost (130209-82-4)

Conditions	Yield
Purification / work up;	A n/a B n/a C 45%

(-)-Corey lactone 5-(4-phenylbenzoate) (31752-99-5) → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 8 steps 1: DCC, phosphoric acid / 1,2-dimethoxy-ethane / a) 18 deg C, 30 min, b) RT, 2 h 2: 1.) NaH / 1.) DME, RT, 1 h, 2.) DME, a) 0 deg C, 30 min, b) RT, 2 h 3: 52 percent / lithium tri-sec-butylborohydride (lithium selectride) / tetrahydrofuran; diethyl ether / 1 h / -78 - -75 °C 4: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 5: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 6: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 7: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 8: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

benzyl bromide (100-39-0) + alcoholic potash → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 8 steps 1: 1.) NaH, 2.) n-BuLi 2: 1.) NaH / 1.) DME, RT, 1 h, 2.) DME, a) 0 deg C, 30 min, b) RT, 2 h 3: 52 percent / lithium tri-sec-butylborohydride (lithium selectride) / tetrahydrofuran; diethyl ether / 1 h / -78 - -75 °C 4: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 5: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 6: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 7: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 8: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(1S,5R,6R,7R)-6-(3-oxo-5-phenyl-1E-pentenyl)-7-<(4-phenylbenzoyl)oxy>-2-oxabicyclo<3.3.0>octan-3-one (41639-72-9) → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 6 steps 1: 52 percent / lithium tri-sec-butylborohydride (lithium selectride) / tetrahydrofuran; diethyl ether / 1 h / -78 - -75 °C 2: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 3: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 4: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 5: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 6: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(1S,5R,6R,7R)-6-<(3S)-3-hydroxy-5-phenyl-1-pentenyl>-7-<(4-phenylbenzoyl)oxy>-2-oxabicyclo<3.3.0>octan-3-one (41639-23-0) → latanoprost (130209-82-4)

Conditions	Yield
Multi-step reaction with 5 steps 1: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 2: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 3: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 4: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 5: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

dimethyl (2-oxo-4-phenylbutyl)phosphonate → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 7 steps 1: 1.) NaH / 1.) DME, RT, 1 h, 2.) DME, a) 0 deg C, 30 min, b) RT, 2 h 2: 52 percent / lithium tri-sec-butylborohydride (lithium selectride) / tetrahydrofuran; diethyl ether / 1 h / -78 - -75 °C 3: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 4: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 5: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 6: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 7: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(1S,5R,6R,7R)-6-<(3R)-3-hydroxy-5-phenyl-1-pentyl>-7(R)-hydroxy-2-oxabicyclo<3.3.0>octan-3-ol → latanoprost (130209-82-4)

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 2: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(1S,5R,6R,7R)-6-<(3R)-3-hydroxy-5-phenyl-1-pentyl>-7(R)-hydroxy-2-oxabicyclo<3.3.0>octan-3-one (145773-21-3) → latanoprost (130209-82-4)

Conditions	Yield
Multi-step reaction with 3 steps 1: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 2: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 3: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(1S,5R,6R,7R)-6-<(3R)-3-hydroxy-5-phenyl-1-pentyl>-7-<(4-phenylbenzoyl)oxy>-2-oxabicyclo<3.3.0>octan-3-one (145773-20-2) → latanoprost (130209-82-4)

Conditions	Yield
Multi-step reaction with 4 steps 1: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 2: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 3: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 4: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

(3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate (38754-71-1) → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 7 steps 1: 1.) NaH / 1.) DME, RT, 1 h, 2.) DME, a) 0 deg C, 30 min, b) RT, 2 h 2: 52 percent / lithium tri-sec-butylborohydride (lithium selectride) / tetrahydrofuran; diethyl ether / 1 h / -78 - -75 °C 3: 78.4 percent / H2, 1 M NaOH / 10percent Pd/C / ethanol / 6 h 4: 85 percent / K2CO3 / methanol / 6 h / Ambient temperature 5: 65 percent / diisobutylaluminium hydride (DIBAL) / toluene; tetrahydrofuran / 1 h / -80 - -72 °C 6: 1.) t-BuOK / 1.) THF, RT, 30 min, 2.) THF, -15 to -10 deg C, 4 h 7: 38 percent / DBU / acetone / 4 h / Ambient temperature View Scheme

latanoprost acid (41639-83-2) → latanoprost (130209-82-4)

Conditions	Yield
With caesium carbonate In water; N,N-dimethyl-formamide

C41H76O5Si3 + C41H76O5Si3 → latanoprost (130209-82-4)

Conditions	Yield
With hydrogenchloride; water In acetone at 0 - 25℃; pH=1 - 3;

C38H68O5Si2 (477884-76-7) → latanoprost (130209-82-4)

Conditions	Yield
With hydrogenchloride; water In tetrahydrofuran at 20℃; for 0.5h;

C38H68O5Si2 (477884-76-7) + C38H68O5Si2 → isopropyl (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate + latanoprost (130209-82-4)

Conditions	Yield
With hydrogenchloride; water In tetrahydrofuran at 20℃; for 0.5h;

2-iodo-propane (75-30-9) + latanoprost L-arginine salt (1224443-39-3) → latanoprost (130209-82-4)

Conditions	Yield
In methanol; water
In methanol; water

(Z)-isopropyl 7-((1R,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((R)-3-(tert-butyldimethylsilyloxy)-5-phenylpentyl)-5-hydroxycyclopentyl)hept-5-enoate (474944-22-4) → latanoprost (130209-82-4)

Conditions	Yield
With hydrogenchloride; water In isopropyl alcohol at 25 - 30℃;

latanoprost acid (41639-83-2) + isopropyl bromide (75-26-3) → latanoprost (130209-82-4)

Conditions	Yield
Stage #1: latanoprost acid With 1,8-diazabicyclo[5.4.0]undec-7-ene In acetone at 20 - 25℃; for 0.166667h; Stage #2: isopropyl bromide In acetone for 0.5h;

tert-butyl[(1S)-3-iodo-1-phenethylpropyl]oxydimethylsilane (876953-73-0) → latanoprost (130209-82-4)

Conditions	Yield
Multi-step reaction with 6 steps 1.1: tert.-butyl lithium / hexane; diethyl ether / 4 h / -78 °C / Inert atmosphere 1.2: 0.92 h / -78 - -50 °C / Inert atmosphere 2.1: diisobutylaluminium hydride / toluene / 3 h / -78 °C 2.2: -50 °C 3.1: dmap; diisopropyl-carbodiimide / tetrahydrofuran / 24 h / 20 - 40 °C 4.1: Grubbs catalyst first generation / dichloromethane / 18 h / 20 - 40 °C / Inert atmosphere 5.1: tetrabutyl ammonium fluoride; ammonium hydrogen difluoride / tetrahydrofuran / 24 h / 20 - 40 °C 6.1: sodium hydride / isopropyl alcohol; mineral oil / 18 h / 20 - 35 °C 6.2: 18 h / 20 °C View Scheme
Multi-step reaction with 5 steps 1.1: tert.-butyl lithium / diethyl ether; pentane / 4 h / -78 - -40 °C / Inert atmosphere; Schlenk technique 1.2: 0.5 h / -30 °C / Inert atmosphere; Schlenk technique 2.1: ozone / methanol; dichloromethane / -78 °C 2.2: -78 - 20 °C 3.1: hydrogenchloride; water / tetrahydrofuran / 16 h / 20 °C 4.1: potassium tert-butylate / tetrahydrofuran / 0.67 h / 0 °C / Inert atmosphere; Schlenk technique 4.2: 0 - 20 °C / Inert atmosphere; Schlenk technique 5.1: caesium carbonate / N,N-dimethyl-formamide / 18 h / 20 °C View Scheme
Multi-step reaction with 6 steps 1.1: tert.-butyl lithium / diethyl ether; pentane / 4 h / -78 - -40 °C / Inert atmosphere; Schlenk technique 1.2: 0.5 h / -30 °C / Inert atmosphere; Schlenk technique 2.1: ozone / methanol; dichloromethane / -78 °C 2.2: -78 - 20 °C 3.1: diisobutylaluminium hydride / dichloromethane / 2 h / -78 °C 4.1: valerianate de potassium / tetrahydrofuran / 0.5 h / 0 °C / Inert atmosphere; Schlenk technique 4.2: 0 - 20 °C / Inert atmosphere; Schlenk technique 5.1: hydrogenchloride; water / tetrahydrofuran / 17 h / 20 °C 6.1: caesium carbonate / N,N-dimethyl-formamide / 18 h / 20 °C View Scheme
Multi-step reaction with 5 steps 1.1: tert.-butyl lithium / diethyl ether / 4 h / -78 - -40 °C / Inert atmosphere 1.2: 1 h / -78 - -20 °C / Inert atmosphere 2.1: ozone / methanol; dichloromethane / -78 °C 2.2: 3.25 h / -78 - 20 °C / Inert atmosphere 3.1: hydrogenchloride; water / tetrahydrofuran / 16 h / 20 °C 4.1: potassium tert-butylate / tetrahydrofuran / 0.67 h / 0 °C / Inert atmosphere 4.2: 1.5 h / 0 - 20 °C / Inert atmosphere 5.1: caesium carbonate / N,N-dimethyl-formamide / 18 h / 20 °C View Scheme

C31H54O3Si2 (1261926-67-3) → latanoprost (130209-82-4)

Conditions

Yield

Multi-step reaction with 5 steps 1.1: diisobutylaluminium hydride / toluene / 3 h / -78 °C 1.2: -50 °C 2.1: dmap; diisopropyl-carbodiimide / tetrahydrofuran / 24 h / 20 - 40 °C 3.1: Grubbs catalyst first generation / dichloromethane / 18 h / 20 - 40 °C / Inert atmosphere 4.1: tetrabutyl ammonium fluoride; ammonium hydrogen difluoride / tetrahydrofuran / 24 h / 20 - 40 °C 5.1: sodium hydride / isopropyl alcohol; mineral oil / 18 h / 20 - 35 °C 5.2: 18 h / 20 °C View Scheme

tert-butyldimethylsilyl chloride (18162-48-6) + latanoprost (130209-82-4) → (Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)cyclopentyl)hept-5-enoate

Conditions	Yield
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 16h;	94%

latanoprost (130209-82-4) → latanoprost acid (41639-83-2)

Conditions	Yield
Stage #1: latanoprost With lithium hydroxide; water In tetrahydrofuran for 16h; Stage #2: With hydrogenchloride In tetrahydrofuran; water	90%

butylboronic acid (4426-47-5) + latanoprost (130209-82-4) → (Z)-isopropyl 7-((1R,5S,6R,7R)-3-butyl-7-((R)-3-hydroxy-5-phenylpentyl)-2,4-dioxa-3-borabicyclo[3.2.1]octan-6-yl)hept-5-enoate

Conditions	Yield
In dichloromethane at 45℃; for 20h; Inert atmosphere;	80%
In dichloromethane at 45℃; for 22h; Inert atmosphere;

(S)-2-{(S)-2-[(S)-2-((S)-2-acetoxypropionyloxy)propionyloxy]propionyloxy}propionic acid + latanoprost (130209-82-4) → C68H94O32

Conditions	Yield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 30℃; for 28h; Inert atmosphere;	60%

(S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-acetoxypropionyloxy)propionyloxy]propionyloxy}propionyloxy)propionic acid + latanoprost (130209-82-4) → propan-2-yl (5Z)-7-[3,5-bis({[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy})-2-(3-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}-5-phenylpentyl)cyclopentyl]hept-5-enoate

Conditions	Yield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 30℃; for 48h; Inert atmosphere;	54%

(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoic acid + latanoprost (130209-82-4) → propan-2-yl (5Z)-7-[3,5-bis({[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy})-2-(3-{[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}-5-phenylpentyl)cyclopentyl]hept-5-enoate

Conditions	Yield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 30℃; for 48h; Inert atmosphere;	37%

(S)-2-[(S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-acetoxypropionyloxy)propionyloxy]propionyloxy}propionyloxy)propionyloxy]-propionic acid + latanoprost (130209-82-4) → propan-2-yl (5Z)-7-[3,5-bis({[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy})-2-(3-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-(acetyloxy)propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}propanoyl]oxy}-5-phenylpentyl)cyclopentyl]hept-5-enoate

Conditions	Yield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 30℃; for 48h; Inert atmosphere;	35%

Upstream product

• 75-30-9 2-iodo-propane 
• 41639-83-2 latanoprost acid 
• 477884-76-7 C₃₈H₆₈O₅Si₂ 
• 141074-06-8 C₂₆H₃₈O₅ 
• 75-26-3 isopropyl bromide 
• 17814-85-6 (4-carboxybutyl)triphenylphosphonium bromide 
• 1240483-22-0 (3aR,4R,5R,6aS)-5-(tert-butyldimethylsilyloxy)-4-((R)-3-(tert-butyldimethylsilyloxy)-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-ol 
• 41723-91-5 4-carboxybutyliden triphenylphosphorane sodium 
• 1240483-21-9 (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 1240483-23-1 (Z)-7-((1R,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((R)-3-(tert-butyldimethylsilyloxy)-5-phenylpentyl)-5-hydroxycyclopentyl)hept-5-enoic acid 
• 1240483-14-0 (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-hydroxy-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 352276-28-9 (1S,5R,6R,7R)-6-<(3S)-3-hydroxy-5-phenyl-1-pentyl>-7(R)-hydroxy-2-oxabicyclo<3.3.0>octan-3-ol 
• 1513876-38-4 (3aR,6aS)-2-oxo-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde 
• 122-97-4 3-Phenyl-1-propanol 

Downstream Products

• 41639-83-2 latanoprost acid 

Relevant articles and documents

Asymmetric Synthesis of Corey Lactone and Latanoprost

Corey lactone was synthesized in a single pot within 152 minutes in a 50 % overall yield via pot and time economical manner. Latanoprost, an antiglaucoma blockbuster drug, was also synthesized via seven pot reaction with five purifications in a 25 % total yield. One of the key reactions is asymmetric domino Michael/Michael reaction, formal [3+2] cycloaddition reaction, of 3-(dimethylphenylsilyl)propenal and ethyl 4-oxo-2-pentenoate, catalyzed by diphenylprolinol silyl ether, which constructed the core substituted cyclopentanone derivative with nearly optically pure form.

NOVEL LATANOPROST INTERMEDIATE AND METHOD FOR PREPARING LATANOPROST WITH HIGH PURITY

The present invention provides a novel latanoprost intermediate represented by chemical formula 1. In chemical formula 1, R is hydrogen or C_1-C_4 alkyl, P is hydrogen or a hydroxy protecting group, at least one P is a hydroxy protecting group. The hydroxy protecting group is represented by chemical formula 2. In chemical formula 2, R^1 is each independently -NO_2 or C_6-C_18 aryl, and R^1 is fused to a phenyl ring to form a C_10-C_18 aromatic ring.COPYRIGHT KIPO 2021

Access to a Key Building Block for the Prostaglandin Family via Stereocontrolled Organocatalytic Baeyer–Villiger Oxidation

A new protocol for the construction of a crucial bicyclic lactone of prostaglandins using a stereocontrolled organocatalytic Baeyer–Villiger (B-V) oxidation was developed. The key B-V oxidation of a racemic cyclobutanone derivative with aqueous hydrogen peroxide has enabled an early-stage construction of a bicyclic lactone skeleton in high enantiomeric excess (up to 95 %). The generated bicyclic lactone is fully primed with two desired stereocenters and enabled the synthesis of the entire family of prostaglandins according to Corey′s route. Furthermore, the reactivity and enantioselectivity of B-V oxidation of racemic bicyclic cyclobutanones were evaluated and 90–99 % ee was obtained, representing one of the most efficient routes to chiral lactones. This study further facilitates the synthesis of prostaglandins and chiral lactone-containing natural products to promote drug discovery.